{"filing":{"accession_number":"0001437749-26-019576","cik":"0001719406","ticker":"NRXPW","company_name":"NRX Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"nrxp20260603_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926019576/nrxp20260603_8k.htm"},"events":[{"id":6897,"run_id":6046,"accession_number":"0001437749-26-019576","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"NRX Pharmaceuticals completed a registered public offering of 5,714,286 shares of common stock at $3.50 per share on June 4, 2026, with an additional 857,142 shares available under a 30-day option, generating approximately $18.8 million in net proceeds (or $21.6 million if the option is fully exercised).","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4443,"accession_number":"0001437749-26-019576","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"NRx Pharmaceuticals entered into an underwriting agreement on June 3, 2026 for a public offering of 5,714,286 shares of common stock at $3.50 per share, with an additional 857,142 shares available under a 30-day option, generating approximately $18.8 million in net proceeds (or $21.6 million if the option is fully exercised). This is a registered public offering that closed on June 4, 2026, representing a material dilutive issuance of equity securities that would affect a reasonable investor's assessment of ownership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:19:37.550917+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4444,"accession_number":"0001437749-26-019576","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses pricing and closing of an \"Offering\" on June 3-4, 2026, with press releases attached as exhibits. While the specific terms are not detailed in this Item 8.01 excerpt, the language \"pricing of the Offering\" and \"closing of the Offering\" is consistent with a securities issuance. Given NRX Pharmaceuticals' status as a smaller pharmaceutical company and the structure of the disclosure, this most likely represents a dilutive equity issuance (private placement, PIPE, or public offering) that would materially affect shareholders through dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:19:37.550917+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4443,"accession_number":"0001437749-26-019576","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"NRx Pharmaceuticals entered into an underwriting agreement on June 3, 2026 for a public offering of 5,714,286 shares of common stock at $3.50 per share, with an additional 857,142 shares available under a 30-day option, generating approximately $18.8 million in net proceeds (or $21.6 million if the option is fully exercised). This is a registered public offering that closed on June 4, 2026, representing a material dilutive issuance of equity securities that would affect a reasonable investor's assessment of ownership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:19:37.550917+00:00","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-06-04"},{"id":4444,"accession_number":"0001437749-26-019576","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses pricing and closing of an \"Offering\" on June 3-4, 2026, with press releases attached as exhibits. While the specific terms are not detailed in this Item 8.01 excerpt, the language \"pricing of the Offering\" and \"closing of the Offering\" is consistent with a securities issuance. Given NRX Pharmaceuticals' status as a smaller pharmaceutical company and the structure of the disclosure, this most likely represents a dilutive equity issuance (private placement, PIPE, or public offering) that would materially affect shareholders through dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:19:37.550917+00:00","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-06-04"}]}